Description: Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
Home Page: www.allogene.com
ALLO Technical Analysis
210 East Grand Avenue
South San Francisco,
CA
94080
United States
Phone:
650 457 2700
Officers
| Name | Title |
|---|---|
| Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. | Co-Founder & Exec. Chairman |
| Dr. David D. Chang M.D., Ph.D. | Co-Founder, Pres, CEO & Director |
| Mr. Joshua A. Kazam | Co-Founder & Director |
| Dr. Eric Thomas Schmidt Ph.D. | Chief Financial Officer |
| Dr. Alison Moore Ph.D. | Chief Technical Officer |
| Mr. Veer Bhavnagri | Gen. Counsel & Compliance Officer |
| Dr. Rafael G. Amado M.D. | Exec. VP of R&D |
| Ms. Barbra Sasu | Chief Scientific Officer |
| Mr. Stephen Cheng | Chief Information Officer |
| Ms. Christine Cassiano | Chief Communications Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.5084 |
| Price-to-Sales TTM: | 4133.631 |
| IPO Date: | 2018-10-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 356 |